Active, not recruitingPhase 2NCT05482971
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
Studying Essential thrombocythemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- PharmaEssentia
- Principal Investigator
- Oleh Zagrijtschuk, MD, PhDPharmaEssentia Corporation
- Intervention
- Ropeginterferon alfa-2b-njft (P1101)(drug)
- Enrollment
- 91 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2027
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- City of Hope National Medical Center, Duarte, California, United States
- Marin Cancer Care, Greenbrae, California, United States
- USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Yale University School of Medicine - Yale Cancer Center, New Haven, Connecticut, United States
- Georgetown University Medical Center, Washington D.C., District of Columbia, United States
- The Winship Cancer Institute Emory University, Atlanta, Georgia, United States
- Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
- Mercy Health - Paducah Medical Oncology and Hematology, Paducah, Kentucky, United States
- Tulane University Medical Center, New Orleans, Louisiana, United States
- Greater Baltimore Medical Center, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Washington University School of Medicine - Division of Oncology, St Louis, Missouri, United States
- Cancer Care Specialists, Reno, Nevada, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05482971 on ClinicalTrials.govOther trials for Essential thrombocythemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07469891A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsPrelude Therapeutics
- RECRUITINGNCT06976918Registry Platform Myelofibrosis and AnemiaiOMEDICO AG
- RECRUITINGNCT07203768A ELN-Multicenter Study on Phenotypic Evolution and Clinical OutcomesFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGPHASE2NCT06517875Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisGlaxoSmithKline
- RECRUITINGNANCT06734637Efficacy and Safety of Peginterferon in ET and PV.Zhenya Hong
- RECRUITINGPHASE1NCT06343805A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)Ajax Therapeutics, Inc.
- RECRUITINGPHASE2NCT06541249MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) TrialIcahn School of Medicine at Mount Sinai
- RECRUITINGPHASE2NCT06552429Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ETXiamen Amoytop Biotech Co., Ltd.